Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.553
Neutral
RSI(14)
49.202
Neutral
STOCH(KDJ)(9,3,3)
20.264
Sell
ATR(14)
2.663
Low Volatility
CCI(14)
-162.512
Sell
Williams %R
84.685
Oversold
TRIX(12,20)
0.337
Sell
StochRSI(14)
1.701
Oversold
Search
Veracyte Inc
VCYTAdd to Watchlist
55.650USD
+0.040+0.07%
Close 07-28 16:00（ET）Quotes delayed by 15 min
4.44BMarket Cap
49.91P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.07%
5 Days
-6.52%
1 Month
-8.00%
6 Months
+44.62%
Year to Date
+32.19%
1 Year
+122.42%
Key Figures
55.600Open
56.630High
740.19KVolume
49.91P/E TTM
42.74P/E Dynamic
--Dividend TTM
0.93%Turnover Ratio
55.610Prev. Close
54.715Low
30.76MTurnover
183.96P/E Static
3.30P/B
0.00%Div Yield TTM
6.40%ROA
50.71052wk High
1.08Volume Ratio
24.14MNet Profit
79.79MShares
1.1150EPS TTM
1.98Beta
6.93%ROE
22.61052wk Low
3.44%Amplitude
72.32%Gross Margin
4.44BMarket Cap
-2.74Reward/Risk
2.78%Risk Rate
TradingKey Stock Score of Veracyte Inc
Currency: USD Updated: 2026-07-28Key Insights
Veracyte Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 57.83.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Veracyte Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Veracyte Inc Highlights
StrengthsRisks
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 43.23% year-on-year.
Fairly Valued
The company’s latest PE is 49.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 96.10M shares, decreasing 1.93% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.21M shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
57.833
Target Price
+2.16%
Upside Space
Veracyte Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
13
analysts
Buy
Current Rating
57.833
Target Price
+2.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Veracyte Inc
VCYT
13
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
56.752
Sell
MA10
57.841
Sell
MA20
57.736
Sell
MA50
52.511
Buy
MA100
43.150
Buy
MA200
41.600
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Veracyte Inc Info
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Ticker SymbolVCYT
CompanyVeracyte Inc
CEOStapley (Marc A)
Websitehttps://www.veracyte.com/
Shareholders
Related Instruments
+1.98%
+0.31%
+1.71%
+2.50%
+0.83%
+2.37%
+4.42%
+2.57%
+2.92%
+2.37%
+1.72%
+2.35%
+3.47%
+3.33%
+4.61%
0.00%
+4.24%
+0.60%
+1.34%
-1.93%Popular Instruments
52652.200
-62.300 (-0.12%)
27551.000
-257.000 (-0.92%)
7413.500
-19.900 (-0.27%)
14603.000
-136.000 (-0.92%)
60673.000
-1649.000 (-2.65%)
6256.100
-43.300 (-0.69%)
81.771
+3.311 (+4.22%)
339.990
+3.080 (+0.91%)
196.950
+0.440 (+0.22%)
4024.800
-3.460 (-0.09%)
FAQs
What is the current price of Veracyte Inc (VCYT)?
The current price of Veracyte Inc (VCYT) is 55.65.
What is the symbol of Veracyte Inc?
The ticker symbol of Veracyte Inc is VCYT.
What is the 52-week high of Veracyte Inc?
The 52-week high of Veracyte Inc is 50.71.
What is the 52-week low of Veracyte Inc?
The 52-week low of Veracyte Inc is 22.61.
What is the market capitalization of Veracyte Inc?
The market capitalization of Veracyte Inc is 4.44B.
Is Veracyte Inc (VCYT) currently rated as Buy, Hold, or Sell?
According to analysts, Veracyte Inc (VCYT) has an overall rating of Buy, with a price target of 57.83.
What is the Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT)?
The Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT) is 0.84.